Ackman And Valeant Team Up To Pursue Takeover Of Allergan – ValueWalk Premium
valeant pharmaceuticals
21Apr2014

Ackman And Valeant Team Up To Pursue Takeover Of Allergan

Activist hedge fund manager Bill Ackman is bringing his sometimes bare-knuckle expertise at the takeover game to Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) as the highly efficient roll-up company targets Botox wrinkle treatment company Allergan, Inc. (NYSE:AGN) with a takeover offer.


Activist hedge fund with successful track record at "encouraging" boards to make the "right" decisions teams with Valeant to acquire Allergan
The

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.

Author

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Related Posts

Average credit card debt

Credit Card Debt Nears $900 Billion, Highest Since 2007

13 May, 2021

Credit card debt could cross $900 billion by the end of the year, bringing the average indebted household’s balance to $7,813, which is the highest amount since the Great... Read More

Updater: The Next Uber Or Airbnb?

14 May, 2021

You have heard of Uber, Lyft and Airbnb but what about Updater? Probably not, but one Australian hedge fund thinks that will change very soon. The Australia-based Newgate Real Estate... Read More

Baupost Q2 Letter

The Three Most Important Words In Investing

14 May, 2021

ValueWalk's Raul Panganiban interviews Gautam Baid, CFA, portfolio manager at an SEC-registered investment advisor based in Salt Lake City, Utah. In this part, Gautam discusses 'margin of safety', the... Read More

VRX Valeant pharmaceuticals

Valeant – Ackman Emails: We Need More Press Releases; Hempton "certifiably crazy"; Risk Of "Death Spiral" And More!

13 May, 2021

The Senate did a late Friday night dump of a huge amount of emails related to Valeant Pharmaceuticals (VRX) and its investigations. We are sifting through the documents but wanted... Read More

Overstock.com, Inc. (OSTK) CEO Patrick Byrne Spying on People – Again

29 May, 2014

Fresh off the heels of a California Judge imposing a $6.8 million judgment against Overstock.com, Inc. (NASDAQ:OSTK) for false advertising and unlawful business practices, the company is in trouble again.... Read More

Kolanovic

JPMorgan's Kolanovic Identifies Important Mean Reversion Trade, Sides With Dalio on QE

13 May, 2021

JPMorgan’s Global Head of Derivatives and Quantitative Strategies examines the recent stock market sell-off, noting potential causation for the jump in stock prices that began yesterday afternoon, all while offering... Read More

Initial Claims Below-300K Mark For Six Consecutive Weeks [CHARTS]

13 May, 2021

Perhaps the king of timely government data, Initial Claims came in at 283K today, an increase of 17K over the incredibly low 266K of the prior week. Overall, the 283K... Read More

The Sequoia Fund’s Secret Sauce

14 May, 2021

In the late 1960s, Warren Buffett decided that he was going to shut down the investment partnerships he had been managing since he returned from working with Benjamin Graham... Read More

Richard Koo Says Fed QE Withdrawal Is Drug Addict's Nightmare

13 May, 2021

The quantitative easing game of chicken is at work, as QE withdrawal is back as a concern with stocks approaching all time highs. When should the U.S. Federal Reserve raise interest... Read More

DB: No, We Are NOT In A Low Return World

14 May, 2021

Over the past few years, plenty of analysts have made the case that after the financial crisis, we've been stuck in a low return world. The introduction of stringent... Read More

X
Saved Articles
X
TextTExtLInkTextTExtLInk
0